BioXcell熱銷產(chǎn)品--RecombiMAb anti-mouse PD-1 (CD279) (D265A)
產(chǎn)品描述:
RMP1-14-CP002單克隆抗體是原始RMP1-14克隆號的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始RMP1-14克隆號相同,但是恒定區(qū)序列已經(jīng)從大鼠IgG2a變?yōu)樾∈驣gG1。RMP1-14-CP002單克隆抗體在Fc片段中也含有D265A突變,使其無法與內(nèi)源性Fcγ受體結(jié)合。
?
RMP1-14-CP002單克隆抗體與小鼠PD-1(程序性死亡-1蛋白,也稱為CD279)反應(yīng)。PD-1是一種50-55 kDa的細(xì)胞表面受體,由Pdcd1基因編碼,屬于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上瞬時表達(dá)。成功清除抗原后,PD-1表達(dá)下降。此外,Pdcd1 mRNA在前B細(xì)胞階段在發(fā)育中的B淋巴細(xì)胞中表達(dá)。PD-1的結(jié)構(gòu)包括一個ITIM(免疫受體酪氨酸抑制基序),表明PD-1負(fù)調(diào)節(jié)TCR信號。PD-1通過結(jié)合它的兩個配體PD-L1和PD-L2發(fā)出信號,這兩個配體都是B7家族的成員。配體結(jié)合后,PD-1信號抑制T細(xì)胞活化,導(dǎo)致增殖、細(xì)胞因子產(chǎn)生和T細(xì)胞死亡減少。此外,已知PD-1在小鼠的外周耐受性和預(yù)防自身免疫性疾病中起關(guān)鍵作用,因?yàn)镻D-1敲除動物表現(xiàn)出擴(kuò)張性心肌病、脾腫大和外周耐受性喪失。誘導(dǎo)的PD-L1表達(dá)常見于許多腫瘤,包括鱗狀細(xì)胞癌、結(jié)腸腺癌和乳腺腺癌。PD-L1過度表達(dá)導(dǎo)致腫瘤細(xì)胞對CD8 T細(xì)胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中,通過用阻斷PD-L1和它的受體PD-1之間的相互作用的抗體治療,腫瘤生長可以暫時被抑制。目前PD-1是免疫療法作為癌癥治療的熱門靶點(diǎn)之一。
?
產(chǎn)品詳情:
產(chǎn)品名稱 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) |
產(chǎn)品貨號 | CP002 |
產(chǎn)品規(guī)格 | 1mg |
反應(yīng)種屬 | Mouse |
克隆號 | RMP1-14-CP002 |
同種型 | Mouse IgG1(switched from rat IgG2a) |
免疫原 | Syrian Hamster BKH cells transfected with mouse PD-1 cDNA |
實(shí)驗(yàn)應(yīng)用 | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody |
產(chǎn)品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 μm filtration |
純化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer(貨號IP0070) |
?
該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻(xiàn)引用:
應(yīng)用 | 文章 |
體內(nèi)PD-1/PD-L信號阻斷 (in vivo blocking of PD-1/PD-L? signaling) | 1.?Triplett, T. A., et al. (2018). 'Reversal of indoleamine 2,3-dioxygenase-mediated cancer? immune suppression by systemic kynurenine depletion with a therapeutic enzyme' Nat? Biotechnol 36(8): 758-764. 2.?Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic? Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 3.?Moynihan, K. D., et al. (2016). 'Eradication of large established tumors in mice by? combination immunotherapy that engages innate and adaptive immune responses' Nat? Med. doi : 10.1038/nm.4200. 4.?Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression? Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. ? 5.?Evans, E. E., et al. (2015). 'Antibody Blockade of Semaphorin 4D Promotes Immune? Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies'? Cancer Immunol Res 3(6): 689-701. 6.?Zelenay, S., et al. (2015). 'Cyclooxygenase-Dependent Tumor Growth through Evasion? of Immunity' Cell 162(6): 1257-1270. 7.?Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk? Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell? Host Microbe 17(5): 628-641. |
?
?
?
更多產(chǎn)品詳情請咨詢?BioXCell?中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?
深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????
廣州:020-87615159???????????上海: 021-34613729
代理品牌網(wǎng)站: m.smblzp.com?
自主品牌網(wǎng)站: www.neobioscience.net??